Drug profile · INN
teclistamab-cqyv
TECVAYLI
teclistamab-cqyv (TECVAYLI) is a t cell surface glycoprotein cd3 binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — teclistamab-cqyv
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
teclistamab-cqyv (TECVAYLI) is a t cell surface glycoprotein cd3 binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
T cell surface glycoprotein CD3 binding agent
Primary target: T cell surface glycoprotein CD3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is teclistamab-cqyv?
teclistamab-cqyv (TECVAYLI) is a t cell surface glycoprotein cd3 binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for teclistamab-cqyv?
TECVAYLI is a marketed brand name for teclistamab-cqyv. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of teclistamab-cqyv?
teclistamab-cqyv has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.